Supernus Pharmaceuticals Inc: Spn-817 Discontinuation Rate Due to Adverse Events (AES) of 22% in Titration Period and 2.4% in Maintenance Period
Supernus Pharmaceuticals Inc:由於不良事件(AES)導致的Spn-817停藥率在滴定期爲22%,維護期爲2.4%
Supernus Pharmaceuticals Inc: Spn-817 Discontinuation Rate Due to Adverse Events (AES) of 22% in Titration Period and 2.4% in Maintenance Period
Supernus Pharmaceuticals Inc:由於不良事件(AES)導致的Spn-817停藥率在滴定期爲22%,維護期爲2.4%
譯文內容由第三人軟體翻譯。